Hemp Lobby Sees Opening In Congress As November THC Deadline Nears

The hemp industry may have found a sliver of daylight in Washington. Whether that turns into actual law is another question.

Just days after IgniteIt reported on Cornbread Hemp’s role in the Medicare-related rollout and High Times detailed the lawsuit that immediately targeted the new federal program, Cornbread Hemp co-founder Jim Higdon said conversations on Capitol Hill suggest congressional staff may be more receptive than expected to a narrow hemp THC fix.

In a LinkedIn video filmed in Washington during meetings with lawmakers and staff, Higdon said hemp stakeholders have seen “an extraordinary amount of understanding among staff looking to help find a solution to the crunch that we’re under.”

That crunch is not theoretical.

The Centers for Medicare & Medicaid Services has already opened a tightly controlled federal pathway allowing certain participating care models to furnish eligible hemp-derived CBD and THC products under the Substance Access Beneficiary Engagement Incentive program. For orally administered products, the framework allows no more than 3 milligrams per serving of tetrahydrocannabinols, alongside other restrictions tied to legality, product type and compliance. But unless Congress changes the broader federal framework before the November deadline, much of the wider intoxicating hemp market could still face a severe reset.

That contradiction has quickly become one of the most important fault lines in hemp policy.

On one side is a federal system now willing, at least in a limited and highly structured setting, to allow low-dose hemp-derived products into patient care. On the other is a looming deadline that industry groups say could effectively collapse much of the category unless lawmakers act in time.

Higdon’s message on the Hill was straightforward: if CMS is comfortable with a 3 milligram per serving threshold in a federal benefit program, Congress should not be forcing the broader market into a far more restrictive standard.

“We have the executive branch with CMS saying that three milligrams per serving is good for their program,” Higdon said in the video. “But until Congress fixes it and says that three milligrams is appropriate, then we’re facing a deadline in November where all that’s gonna crash into 0.4 milligrams per container.”

He also pointed to a second industry priority: preserving a path for low-dose hemp beverages up to 5 milligrams through a three-tier distribution structure. That idea, which has circulated in alcohol-adjacent policy discussions, would go beyond the narrow CMS pilot and into regular commerce. For now, it remains part of the lobbying ask, not settled federal policy.

That distinction matters.

The CMS framework is real, but narrow. It does not mean broad retail reimbursement, blanket Medicare coverage or a federal green light for the entire hemp THC marketplace. Participating organizations must elect the benefit, submit an implementation plan and obtain CMS approval. Products must meet strict eligibility requirements, and access is confined to specific care models rather than the general public.

Still, for hemp operators, the symbolism is hard to ignore. After years of regulatory ambiguity, the federal government has now drawn at least one line that acknowledges a limited role for compliant low-dose hemp cannabinoids in care delivery.

That is why Higdon’s comments matter beyond Cornbread Hemp’s own business interests.

His company has obvious skin in the game. Cornbread recently announced that it had secured an exclusive supply arrangement connected to the federal benefit rollout, making Higdon both a useful source and an interested stakeholder in the outcome. But his latest remarks offer a useful window into how the industry is trying to turn a narrow administrative opening into a broader legislative solution.

The larger question is whether Congress can move fast enough.

The November deadline is closing in, and hemp operators are now trying to persuade lawmakers that the emerging federal posture should be coherence, not contradiction: one standard for a tightly controlled patient-care lane, another for responsible low-dose commerce, and something more realistic than a policy framework that tolerates THC in one federal channel while threatening to squeeze much of the broader market out of existence.

That does not mean the fix is close. It means the argument is getting a hearing.

For an industry that has spent months bracing for collapse, that alone is enough to count as movement.

Photo by Caleb Perez on Unsplash